空气污染与接受核苷(酸)类似物治疗的慢性乙型肝炎患者死亡率相关
该研究纳入697例接受核苷(酸)类似物治疗的慢性乙型肝炎患者,随访3798.1人年,全因死亡年发生率为1.1/100人年。肝硬化、年龄和治疗前GGT水平与全因死亡最强相关;在肝硬化患者中,NOx浓度每增加1 ppb与全因死亡相关(HR 1.045),NOx>25.5 ppb者死亡率更高(HR 2.49)。结论认为空气污染影响接受核苷(酸)类似物治疗的CHB患者全因死亡率,长期NOx暴露可能增加肝硬化患者的肝相关死亡率。
要点
- 697例接受核苷(酸)类似物治疗的CHB患者随访3798.1人年,全因死亡年发生率为1.1/100人年。
- 肝硬化(HR 3.95)、年龄(HR 1.07)和治疗前GGT(HR 1.004)与全因死亡最强相关。
- 肝硬化患者中NOx>25.5 ppb与更高全因死亡发生率相关(HR 2.49)。
核心结论
- 空气污染影响接受核苷(酸)类似物治疗的慢性乙型肝炎患者全因死亡率。
- 长期NOx暴露可能增加接受核苷(酸)类似物治疗的慢性乙型肝炎合并肝硬化患者的肝相关死亡率。
研究设计与样本
- 研究纳入697例接受核苷(酸)类似物治疗的慢性乙型肝炎患者,分析死亡发生率及危险因素。
- 每日空气污染物浓度从入组前一年开始估算。
- 随访期间共3798.1人年。
主要发现
- 全因死亡年发生率为1.1/100人年。
- 与全因死亡最强相关的因素为肝硬化(HR 3.95,95%CI 1.69-9.23,p=0.02)、年龄(HR 1.07,95%CI 1.03-1.17,p<0.001)和治疗前GGT水平(HR 1.004,95%CI 1.001-1.006,p=0.004)。
- 肝硬化患者中与全因死亡相关的因素为年龄(HR 1.08,95%CI 1.04-1.12,p<0.001)、治疗前GGT水平(HR 1.004,95%CI 1.001-1.008,p=0.01)、血小板计数(HR 0.988,95%CI 0.977-0.998,p=0.02)和NOx浓度(每单位增量,ppb)(HR 1.045,95%CI 1.001-1.091,p=0.046)。
- 肝硬化患者中预测全因死亡的最佳NOx截断值为25.5 ppb(AUROC 0.63,p=0.03)。
- NOx水平>25.5 ppb与肝硬化患者更高的死亡发生率相关(HR 2.49,95%CI 1.03-6.02,p=0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Air pollution is associated with advanced liver fibrosis in patients with chronic liver diseases, including chronic hepatitis B (CHB). This study aimed to investigate the association between air pollution and mortality in patients with CHB treated with nucleotide/nucleoside analogues. METHODS: We enrolled 697 patients with CHB treated with nucleotide/nucleoside analogues and analysed the incidence and risk factors for mortality. Daily air pollutant concentrations were estimated from the year before enrolment. RESULTS: All-cause mortality showed an annual incidence of 1.1/100 person-years after a follow-up period of 3798.1 person-years. Factors with the strongest association with all-cause mortality were liver cirrhosis (hazard ratio [HR]/95% confidence interval [CI]: 3.95/1.69-9.23; p = 0.02), age ([HR]/CI: 1.07/1.03-1.17, p < 0.001) and pre-treatment gamma-glutamyl transferase (GGT) levels (HR/CI: 1.004/1.001-1.006, p = 0.004). Among patients with cirrhosis, the factors associated with all-cause mortality were age (HR/CI: 1.08/1.04-1.12, p < 0.001), pre-treatment GGT levels (HR/CI: 1.004/1.001-1.008, p = 0.01), platelet count (HR/CI: 0.988/0.977-0.998, p = 0.02) and NOx concentration (per unit increment, ppb) (1.045/1.001-1.091; p = 0.046). The best NOx cut-off value for predicting all-cause mortality in patients with cirrhosis was 25.5 ppb (AUROC 0.63; p = 0.03). NOx levels > 25.5 ppb were associated with a higher incidence of mortality in patients with cirrhosis (HR/CI:2.49/1.03-6.02; p = 0.04). CONCLUSIONS: Air pollution influences all-cause mortality in patients with CHB receiving nucleotide/nucleoside analogue therapy. Long-term NOx exposure may increase liver-related mortality in patients with chronic hepatitis B and cirrhosis receiving nucleotide/nucleoside analogue treatment.
引用
- Jang TY, Zeng YT, Liang PC, et al. Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues. Aliment Pharmacol Ther. 2025. PMID: 39968810. doi:10.1111/apt.70019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。